Advertisement
Prior to joining MINRAD, Goupil was the Chief Technical Officer and VicePresident of Research and Development at Biocure, an early stage medicaldevice company based in Norcross, GA. Earlier in his career, Goupil heldvarious leadership positions at Boston Scientific, Datascope and Pharmaciafocusing on the management of the research and development process andoverseeing new business development. Goupil received a Bachelor of Science inChemistry from Niagara University, a Masters of Science in Civil Engineeringfrom the University of Cincinnati, and a Doctor of Philosophy in PhysicalChemistry from Clarkson College of Technology.
Advertisement
Most recently, Vollrath was a consultant focusing on clients in thepharmaceuticals, chemicals, biotech and manufacturing industries. Prior tothat, Vollrath held the Director of Operations positions at Aerojet FineChemicals and various management positions at Abbott Laboratories focusing onchemical manufacturing operations. Vollrath received his Bachelor of Sciencedegree in Chemical Engineering from the University of Wisconsin and hisMasters of Business Administration from Lake Forest Graduate School ofBusiness.
In commenting on the new hires, Bill Burns, CEO of MINRAD stated; "Dennisand Terry both bring proven track records to MINRAD, which should allow forthe acceleration of the Company's goal achievement."
About the Company
MINRAD International, Inc. is an interventional pain management companywith real-time image guidance, anesthesia and analgesia, and conscioussedation product lines. The real-time image guidance products facilitateminimally invasive surgery especially for pain management and have broadapplications in orthopedics, neurosurgery, and interventional radiology. Thesedevices enable medical professionals to improve the accuracy of interventionalprocedures and reduce radiation exposure. MINRAD International alsomanufactures and markets generic inhalation anesthetics for use in connectionwith human and veterinary surgical procedures. The company is developing adrug/drug delivery system for conscious sedation, which, similar to nitrousoxide in dental surgery, provides a patient with pain relief without loss ofconsciousness. Additional information can be found at the company's website,http://www.minrad.com .
The information contained in this news release, other than historicalinformation, consists of forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995. These statements may involverisks and uncertainties that could cause actual results to differ materiallyfrom those described in such statements. Factors that may cause actual resultsto differ materially from those expressed or implied by its forward-lookingstatements include, but are not limited to, Minrad International's limitedoperating history and business development associated with being a growthstage company; its dependence on key personnel; its need to attract and retaintechnical and managerial personnel; its ability to execute its businessstrategy; the intense competition it faces; its ability to protect itsintellectual property and proprietary technologies; its exposure to productliability claims resulting from the use of its products; general economic andcapital market conditions; financial conditions of its customers and theirperception of its financial condition relative to that of its competitors; aswell as those risks described under the heading "Risk Factors" of MINRADInternational's Form 10-KSB, filed with the Securities and Exchange Commissionon March 29, 2007. Although Minrad International, Inc. believes that theexpectations reflected in su
